Marker Therapeutics (MRKR) Liabilities and Shareholders Equity (2010 - 2026)

Marker Therapeutics (MRKR) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $17.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $17.4 million, up 2.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.0 million (up 18.52% YoY), and the FY2025 annual result was $19.1 million, down 13.4% from the prior year.
• Liabilities and Shareholders Equity slipped to $17.4 million in Q1 2026 per MRKR's latest filing, from $19.1 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $55.0 million in Q1 2022 and troughed at $10.9 million in Q3 2024.
• A 5-year average of $24.6 million and a median of $19.5 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity slumped 58.04% in 2023, then soared 99.21% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $34.4 million in 2022, then plunged by 50.24% to $17.1 million in 2023, then grew by 28.58% to $22.0 million in 2024, then dropped by 13.4% to $19.1 million in 2025, then retreated by 8.58% to $17.4 million in 2026.
• Business Quant data shows MRKR's Liabilities and Shareholders Equity at $17.4 million in Q1 2026, $19.1 million in Q4 2025, and $21.7 million in Q3 2025.